Ziyuglycoside II
Based on 1 publication(s) in Google Scholar
Ziyuglycoside II is a triterpenoid saponin compound extracted from Sanguisorba officinalis L.. Ziyuglycoside II induces reactive oxygen species (ROS) production and apoptosis. Anti-inflammation and anti-cancer effect.
For research use only. We do not sell to patients.
- Purity : 99.88%
- CAS No.: 35286-59-0
- Formula: C35H56O8
- Molecular Weight:604.81
-
Storage:
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Ziyuglycoside II
More
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
Cell Imaging/Staining
-
In Vivo Efficacy Study
-
IHC
-
Apoptosis Analysis
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HCT-116 | IC50 |
10.8 μM
Compound: 25
|
Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 24 hrs by CellTiter 96 Aqueous One Solution Cell Proliferation Assay
Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell growth measured after 24 hrs by CellTiter 96 Aqueous One Solution Cell Proliferation Assay
|
[PMID: 38142509] |
| SW480 | IC50 |
11.3 μM
Compound: 25
|
Antiproliferative activity against human SW480 cells assessed as inhibition of cell growth measured after 24 hrs by CellTiter 96 Aqueous One Solution Cell Proliferation Assay
Antiproliferative activity against human SW480 cells assessed as inhibition of cell growth measured after 24 hrs by CellTiter 96 Aqueous One Solution Cell Proliferation Assay
|
[PMID: 38142509] |
In Vitro
Ziyuglycoside II (10-60 μM; 24 h and 48 h) inhibits MDA-MB-435 cells growth in a dose-dependent manner. The IC50 of Ziyuglycoside II at 24 h and 48 h is 5.92 μM and 4.74 μM, respectively[1].
?
Ziyuglycoside II (5-25 μM) induces G0/G1 and S phase arrest in MDA-MB-435 cells at 24 h[1].
?
Ziyuglycoside II (5-25 μM; 24 hours) significantly increases apoptotic rate of MDA-MB-435 cells[1].
?
Ziyuglycoside II (5-25 μM; 24 hours) increases expressions of both p53 and p21 in MDA-MB-435 cells, which effect is dose-dependent[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:MDA-MB-435 cells
-
Concentration:10, 20, 30, 40, 50, 60 μM
-
Incubation Time:24 hours and 48 hours
-
Result:The IC50 at 24 h and 48 h was 5.92 μM and 4.74 μM, respectively.
-
Cell Line:MDA-MB-435 cells
-
Concentration:5, 10, 25 μM
-
Incubation Time:24 hours
-
Result:Induced G0/G1 and S phase arrest.
-
Cell Line:MDA-MB-435 cells
-
Concentration:5, 10, 25 μM
-
Incubation Time:24 hours
-
Result:The apoptotic rate was significantly increased in comparison to that of the control.
-
Cell Line:MDA-MB-435 cells
-
Concentration:5, 10, 25 μM
-
Incubation Time:24 hours
-
Result:Treatment resulted in increased expressions of both p53 and p21.
Chemical Information
-
CAS No. 35286-59-0
-
Appearance Solid
-
Molecular Weight 604.81
-
Formula C35H56O8
-
Color White to off-white
-
SMILES
C[C@@H]1CC[C@@](CC[C@]2(C)C3=CC[C@@]4([H])[C@@]2(C)CC[C@]5([H])[C@]4(C)CC[C@H](O[C@@]6([H])[C@H](O)[C@@H](O)[C@@H](O)CO6)C5(C)C)(C(O)=O)[C@@]3([H])[C@]1(C)O
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
-20°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Front Pharmacol
Repurposing Ziyuglycoside II Against Colorectal Cancer via Orchestrating Apoptosis and Autophagy. [Abstract]2020 Sep 18:11:576547. PMID: 33071789
Ziyuglycoside II purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2020 Sep 18:11:576547. [Abstract]
MTT assay of colorectal cancer lines incubated with the designated concentrations of Ziyuglycoside II (Ziyu II) (0, 5, 10, 15, 20, 25, 30 μM) for 24 h.
Ziyuglycoside II purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2020 Sep 18:11:576547. [Abstract]
Colony formation assay of DLD-1 and HCT116 cells intervented with the designated concentrations of Ziyuglycoside II (Ziyu II) (0, 10, 20 μM) for 2 weeks.
Ziyuglycoside II purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2020 Sep 18:11:576547. [Abstract]
Photograph of dissected tumors derived from control or Ziyuglycoside II (Ziyu II) (50 mg/kg/day, i.g.)-treated mice
Ziyuglycoside II purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2020 Sep 18:11:576547. [Abstract]
The expression of Ki67 was detected by IHC in tumor xenografts treated with Ziyuglycoside II (Ziyu II) (50 mg/kg/day, i.g.).
Ziyuglycoside II purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2020 Sep 18:11:576547. [Abstract]
DLD-1 and HCT116 cells were subjected to Ziyuglycoside II (Ziyu II) (0, 10, 20 μM) Dox 10 uM for 24 h, and flow cytometric analysis of apoptosis.
Ziyuglycoside II purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2020 Sep 18:11:576547. [Abstract]
The protein of LC3, Atg7, and ATG5 of DLD-1 and HCT116 cells were detected by Western blot after 24 h of treatment with Ziyuglycoside II (Ziyu II) (0, 10, 20 μM).
Ziyuglycoside II purchased from MedChemExpress. Usage Cited in: Front Pharmacol. 2020 Sep 18:11:576547. [Abstract]
The colocalization of endogenous LC3 with LAMP1 was detected by immunofluorescent analysis after treatment of Ziyuglycoside II (Ziyu II) and CQ (10 mM) for 24 h, respectively.
Solvent & Solubility
In Vitro:
DMSO : 50 mg/mL (82.67 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 0.83 mg/mL (1.37 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 0.83 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (8.3 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 0.83 mg/mL (1.37 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 0.83 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (8.3 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Purity & Documentation
-
Data Sheet (280 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Zhu X, et al. Ziyuglycoside II inhibits the growth of human breast carcinoma MDA-MB-435 cells via cell cycle arrest and induction of apoptosis through the mitochondria dependent pathway. Int J Mol Sci. 2013 Sep 3;14(9):18041-55. [Content Brief]
[2]. Zhu X, et al. Ziyuglycoside II induces cell cycle arrest and apoptosis through activation of ROS/JNK pathway in human breast cancer cells. Toxicol Lett. 2014 May 16;227(1):65-73. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.6534 mL | 8.2671 mL | 16.5341 mL | 41.3353 mL |
| 5 mM | 0.3307 mL | 1.6534 mL | 3.3068 mL | 8.2671 mL | |
| 10 mM | 0.1653 mL | 0.8267 mL | 1.6534 mL | 4.1335 mL | |
| 15 mM | 0.1102 mL | 0.5511 mL | 1.1023 mL | 2.7557 mL | |
| 20 mM | 0.0827 mL | 0.4134 mL | 0.8267 mL | 2.0668 mL | |
| 25 mM | 0.0661 mL | 0.3307 mL | 0.6614 mL | 1.6534 mL | |
| 30 mM | 0.0551 mL | 0.2756 mL | 0.5511 mL | 1.3778 mL | |
| 40 mM | 0.0413 mL | 0.2067 mL | 0.4134 mL | 1.0334 mL | |
| 50 mM | 0.0331 mL | 0.1653 mL | 0.3307 mL | 0.8267 mL | |
| 60 mM | 0.0276 mL | 0.1378 mL | 0.2756 mL | 0.6889 mL | |
| 80 mM | 0.0207 mL | 0.1033 mL | 0.2067 mL | 0.5167 mL |
Ziyuglycoside II Related Classifications
HY-N0332 Related Classifications
Powered by Bioz